- Home
- MDIA vs NRXS Comparison
MDIA vs NRXS Comparison
Compare MDIA & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MDIA | NRXS |
|---|---|---|
| Founded | 2019 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.8M | 78.9M |
| IPO Year | 2019 | 2023 |
Fundamental Metrics
Financial Performance| Metric | MDIA | NRXS |
|---|---|---|
| Price | $1.04 | $6.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $11.00 |
| AVG Volume (30 Days) | 9.2K | ★ 139.8K |
| Earning Date | 11-18-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 22.13 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $133,336,000.00 | $3,569,282.00 |
| Revenue This Year | N/A | $132.54 |
| Revenue Next Year | N/A | $138.55 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 39.52 | 32.89 |
| 52 Week Low | $0.54 | $2.21 |
| 52 Week High | $1.64 | $9.33 |
Technical Indicators
Market Signals| Indicator | MDIA | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 44.88 | 50.34 |
| Support Level | $0.97 | $6.51 |
| Resistance Level | $1.07 | $7.75 |
| Average True Range (ATR) | 0.07 | 0.50 |
| MACD | -0.01 | -0.09 |
| Stochastic Oscillator | 19.05 | 20.69 |
Price Performance
Historical ComparisonAbout MDIA Mediaco Holding Inc.
MediaCo Holding Inc is a radio broadcasting media company operating in radio and digital advertising, premium programming, and events. It has two radio stations, WQHT-FM and WBLS-FM, which serve the New York City metropolitan area. The company generates revenue from radio and outdoor advertising sales, events including sponsorships and ticket sales, licensing, and syndication. The company has two business segments: the Audio segment and the Video segment.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).